There’s no end in sight when you have diabetes — but is there ever a time when it’s right to quit your meds? In this edition of our weekly diabetes advice column, Ask D’Mine, a couple of our readers are wondering if their meds are no longer so good…
As per usual, we’ve got some info-packed responses from host Wil Dubois, diabetes author and community educator and also a veteran type 1 himself.
{Need help navigating…
The biggest thing in diabetes headlines of late is Bydureon, the first and only once-a-week drug to help type 2 diabetics keep their sugars in check, which is newly approved by the FDA. Amylin’s stock price is up, and the pharma blogosphere is all abuzz. But if you’re like us, you may be wondering what the really big deal is. New type 2 drugs come out all the time, don’t they?
Well, for one thing,…
Paula Deen is facing the music, on the eve of her birthday nonetheless (tomorrow). She and her publicist must have had a phone-a-thon today as she made herself available to the media, inevitably to answer to accusations of hypocrisy, profiteering, and just being a downright bad role model for people with diabetes everywhere. I got a scant 15 minutes on the phone with her, and all I can say is, she sure sounded like a…
Read more »
In case you haven’t heard, famous butter-and-cream Southern supreme chef Paula Deen has announced that she is a type 2 diabetic… and that she has partnered with Novo Nordisk in a campaign promoting their drug, Victoza. The way the Internet is all abuzz with this news, you’d think President Obama had been diagnosed with diabetes. But apparently the fact that Paula Deen, renowned for her carb-laden cookbooks and television shows, now has type 2 diabetes…
Read more »
In the area of beta cell preservation, there’s a (sort of) new name in the spotlight: Andromeda Biotech, Ltd. with its DiaPep277 treatment. Based in Israel, this company announced last month that phase III clinical trials showed significant preservation of C-peptide levels, a marker for assessing insulin secretion by pancreatic cells. Andromeda joins the ranks of companies like Tolerx and Macrogenics/Lilly, who’ve been vocal about their work to preserve beta cell functioning in newly diagnosed patients…
Read more »